Carolina BioOncology (CBI) enters into an Agreement with Xcell Biosciences (XcellBio) for Advanced Immunotherapeutic Development
Published: Aug 08, 2018
XcellBio, a proprietary provider of primary cell control technologies for immunotherapeutic solutions today announced a collaboration with Carolina BioOncology Institute (CBI) to further pre-clinical development of true personalized medicine therapies. CBI will utilize XcellBio's products to expand and profile patient derived tumor and immune cells through the use of the AVATAR™ systems in CBI's pre-clinical development and validation programs. The novel technology and research program mimics the immune and tumor microenvironments providing fine control over both the quantity and quality of cells produced to develop the highest level cell therapies.
"With our proprietary primary cell control platform, we provide deeper insight into cellular profile and responses in the various HME such as the Tumor Microenvironment (TME)," said Janette Phi, Chief Operations Officer of XcellBio. "We are excited to collaborate with Carolina BioOncology Institute in demonstrating the utility of our AVATAR™ technologies for the development of adoptive cell therapies and a predictive therapeutics approach."
"We are very pleased to be working with XcellBio in this collaborative way. We are validating this technology for our patient tumor and T-cell therapeutics pre-clinical development. This collaboration will enable us to continue our mission of providing cutting edge clinical research and development for our cancer patients," said Founder and President of CBI Dr. John Powderly.
About Carolina BioOncology Institute (CBI)
Here at CBI, our mission is to provide the highest level of comprehensive and quality medical care possible. To accomplish our mission, we combine cutting edge research with personalized clinical care. Headquartered in Huntersville, NC, CBI provides quality cancer care in a community based setting near Charlotte, NC. From North Carolina to Northern California, patients travel from near and far to take advantage of our access to early phase immunotherapy clinical trials. CBI is aptly situated and equipped to handle each patient as a unique individual. For more information, please visit www.carolinabiooncology.org.
About Xcell Biosciences
Xcell Biosciences is a San Francisco-based life science start-up company that has developed a proprietary cell control system for use in research, drug development, and regenerative medicine applications. The technology delivers simple, standardized methods for fine control of tumor cells, stem cells, and immune cells. This novel platform enables direct disease insights through its uniquely differentiated cell control capabilities. These include the capability to easily grow primary human cells, flexibly modulate cellular phenotype and function, and dramatically improve the delivery of molecular materials into cells. The technology is currently in use for research and development applications ranging from novel cancer biomarker discovery to cell-based immunotherapy lead optimization. For more information, please visit www.xcellbio.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/carolina-biooncology-cbi-enters-into-an-agreement-with-xcell-biosciences-xcellbio-for-advanced-immunotherapeutic-development-300694271.html
SOURCE Xcell Biosciences